![[8]-Shogaol](https://file.medchemexpress.com/product_pic/hy-n2435.gif "Click to View [8]-Shogaol Product Detail")
Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
33 Results for "
synovial cells
" in MedChemExpress (MCE) Product Catalog:
Products (33)
33 Results for "synovial cells" in MCE Product Catalog:
4
4 Cited Publications
Cat. No.: HY-N2435
CAS No.: 36700-45-5
1
Collagenase, Type VI (EC 3.4.24.3) is a collagenase that can degrade type VI collagen. Type VI collagen is a component of cell membranes in various tissues (such as skin, heart, blood vessels, cartilage, and synovial fluid). Excessive collagenase can cause extracellular matrix lesions. Collagenase is also a biomarker for tumor invasion and metastasis. Collagenase, Type VI can specifically act on the peptide bond between proline and glycine. This feature can be used to quickly and sensitively detect its concentration level in experiments using corresponding modified electrodes .
Cat. No.: HY-B0808
CAS No.: 21256-18-8
Synonyms: Oxaprozinum; Wy21743
Oxaprozin is an orally active and potent COX inhibitor, with IC50 values of 2.2 μM for human platelet COX-1 and and 36 μM for IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of NF-κB. Oxaprozin induces cell apoptosis. Oxaprozin shows anti-inflammatory activity. Oxaprozin-mediated inhibition of the Akt/IKK/NF-κB pathway contributes to its anti-inflammatory properties .
Cat. No.: HY-P99781
CAS No.: 1610761-46-0
Synonyms: MLN-1202
Target:
Research Areas:
Cat. No.: HY-159579
CAS No.: 3055592-99-6
Target:
Research Areas:
CW-3308 is an orally active BRD9 PROTAC degrader with an DC50 of 92 nM. CW-3308 forms a ternary complex with BRD9 and cereblon to mediate BRD9 degradation. CW-3308 inhibits the viability of synovial sarcoma and rhabdoid tumor cells. CW-3308 reduces BRD9 protein levels in xenograft tumor tissues and suppresses tumor growth in xenograft models. CW-3308 can be used for the research of synovial sarcoma and rhabdoid tumors .
Cat. No.: HY-148739
CAS No.: 2170679-42-0
Target:
Research Areas:
dBRD 9-A is a selective BRD9 PROTAC degrader. dBRD 9-A induces near complete BRD9 degradation dependent on E3 ubiquitin ligase CRBN and BRD9 bromodomain engagement, and drives loss of BRD9 chromatin binding genome-wide. dBRD 9-A downregulates oncogenic SS18-SSX-driven transcriptional programs, super enhancer-associated gene expression, and SS18-SSX1 super enhancer binding, and depletes GBAF complex members GLTSCR1/1L from SS18-SSX complexes. dBRD 9-A induces cell cycle arrest and increases apoptosis in synovial sarcoma cells. dBRD 9-A can be used for the research of synovial sarcoma .
Cat. No.: HY-N0475
CAS No.: 74285-86-2
Synonyms: Hypolide; (+)-Triptophenolide
Synonyms: ISC-27864; GRC-27864
Target:
Research Areas:
Zaloglanstat (ISC-27864; GRC-27864) is a selective, orally active microsomal mPGES-1 inhibitor. Zaloglanstat has an IC50 of 5 nM for human mPGES-1 without significant inhibitory effect on COX-1/2 (IC50 >10 μM). Zaloglanstat blocks the conversion of arachidonic acid metabolite prostaglandin PGH2 to prostaglandin PGE2, thereby inhibiting inflammation-related PGE2 overproduction and reducing inflammatory responses and pain. Zaloglanstat inhibits IL-1β-induced PGE2 release in A549 cells and human synovial fibroblasts in vitro. Zaloglanstat inhibits PGE2 release in pig and dog whole blood with IC50s of 161 nM and 154 nM, respectively. Zaloglanstat can be used in the study of asthma, osteoarthritis, and neurodegenerative diseases .
Cat. No.: HY-156744
Purity: 98.87%
Target:
Research Areas:
DBr-1 is a potent BRD9 PROTAC degrader with a DC50 of 90 nM. DBr-1 mediates the ubiquitination and proteasomal degradation of BRD9 via the ubiquitin-proteasome pathway. DBr-1 is applicable to research related to renal cell carcinoma and synovial sarcoma .
Target:
Research Areas:
NDMC101 is a potent osteoclastogenesis inhibitor and inhibits osteoclast differentiation via down-regulation of NFATc1-modulated gene expression. NDMC101 is similar to the DPP4 substrate and is a significant inhibitor of early T-cell activation via DPP4 inhibition. NDMC101can be used for study of bone disorders, such as rheumatoid arthritis, and synovial inflammation et al .
Cat. No.: HY-167692
CAS No.: 850019-35-1
JI069 is a novel JAK-STAT inhibitor that demonstrates potent activity in suppressing Th1, Th2, and Th17 differentiation while promoting iTreg differentiation. JI069 effectively inhibits STAT3 activation as well as the activation of other STATs, including STAT1, STAT5, and STAT6. JI069 has shown significant therapeutic potential in alleviating symptoms of collagen-induced arthritis in mice while inhibiting cytokine production from T cells and the phosphorylation of STAT3 in synovial cells.
Cat. No.: HY-P4096
CAS No.: 329004-38-8
Target:
Research Areas:
Synonyms: M-2
Target:
Research Areas:
S-methyl-KE-298 is an active metabolite of KE-298. KE-298 inhibits matrix metalloproteinase (MMP-1) production from rheumatoid arthritis (RA) synovial cells.
Cat. No.: HY-178345
Synonyms: ZZ7
Research Areas:
ZZ7-23-022 (ZZ7) is a selective BRD9 molecule glue degrader. ZZ7-23-022 effectively degrades BRD9 in synovial sarcoma cells, but does not affect cardiomyocytes. ZZ7-23-022 can be used for the research of cancer .
Cat. No.: HY-N16372
CAS No.: 1424195-39-0
Category:
Target:
Research Areas:
PROTAC BRD9 Degrader-6 (Compound D1) is a racemic PROTAC degrader that recruits cereblon to induce targeted degradation of BRD9. PROTAC BRD9 Degrader-6 has an IC50 of 0.13 nM in SYO-1 cells. It can be used in research on BAF complex-related diseases, such as cancer, infections and synovial sarcoma .
Cat. No.: HY-101671R
CAS No.: 143584-75-2
Synonyms: M-2 (Standard)
Target:
Research Areas:
S-methyl-KE-298 (Standard) is the analytical standard of S-methyl-KE-298. This product is intended for research and analytical applications. S-methyl-KE-298 is an active metabolite of KE-298. KE-298 inhibits matrix metalloproteinase (MMP-1) production from rheumatoid arthritis (RA) synovial cells.
Cat. No.: HY-B0808S1
CAS No.: 2933758-40-6
Synonyms: Oxaprozinum-d5; Wy21743-d5
Cat. No.: HY-B0808A
CAS No.: 174064-08-5
Synonyms: Oxaprozinum potassium; Wy21743 potassium
Oxaprozin potassium is an orally active and potent COX inhibitor, with IC50 values of 2.2 μM for human platelet COX-1 and and 36 μM for IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin potassium also inhibits the activation of NF-κB. Oxaprozin potassium induces cell apoptosis. Oxaprozin potassium shows anti-inflammatory activity. Oxaprozin potassium-mediated inhibition of the Akt/IKK/NF-κB pathway contributes to its anti-inflammatory properties .
Cat. No.: HY-13478
CAS No.: 928344-12-1
Target:
Research Areas:
AS1940477 (Compound 3f) is an orally active p38 MAPK inhibitor. AS1940477 inhibits the enzymatic activity of recombinant p38α and β isoforms. AS1940477 inhibits the production of pro-inflammatory cytokines (including TNFα, IL-1β, and IL-6) in human synovial interstitial cells and animal models of inflammation. AS1940477 can be used in research on inflammatory diseases .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
